Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) EBIT: 2023-2024

Historic EBIT for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to -$331.4 million.

  • Inhibrx Biosciences' EBIT rose 27.75% to -$33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.0 million, marking a year-over-year increase of 58.35%. This contributed to the annual value of -$331.4 million for FY2024, which is 51.19% down from last year.
  • Inhibrx Biosciences' EBIT amounted to -$331.4 million in FY2024, which was down 51.19% from -$219.2 million recorded in FY2023.
  • Over the past 5 years, Inhibrx Biosciences' EBIT peaked at -$219.2 million during FY2023, and registered a low of -$331.4 million during FY2024.
  • Its 2-year average for EBIT is -$275.3 million, with a median of -$275.3 million in 2023.
  • Data for Inhibrx Biosciences' EBIT shows a maximum YoY plummeted of 51.19% (in 2024) over the last 5 years.
  • Inhibrx Biosciences' EBIT (Yearly) stood at -$219.2 million in 2023, then slumped by 51.19% to -$331.4 million in 2024.